Matinas BioPharma faces equity shortfall with $3.02M shareholder equity Matinas BioPharma's shareholder equity fell to $3.02M in March 2026. The company posted losses, causing its equity to drop below the required $4M threshold. The NYSE American notice gives Mat
Matinas BioPharma faces equity shortfall with $3.02M shareholder equity
Matinas BioPharma’s shareholder equity fell to $3.02M in March 2026.
The company posted losses, causing its equity to drop below the required $4M threshold.
The NYSE American notice gives Matinas BioPharma until 2027 to comply with the minimum shareholder equity requirement.
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
